Targeted combination nanotherapeutics in cancer a real promise

Nanomedicine

Volumn 10, Issue 12, 2015, Pages 1855-1857

  Shiekh, Farooq A ^a   Mian, Sarah H ^a   Arja, Sateesh B ^a   Rao, M V Raghavendra ^a  

^a Avalon University School of Medicine   (Netherlands)

Author keywords

cancer; combined therapeutics; genomic medicine; multi targets; nanomedcine; nanoships

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; NANOCARRIER; SMALL INTERFERING RNA; VACCINE; NANOCAPSULE;

BIOLOGICAL ACTIVITY; CANCER CELL; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CLINICAL MEDICINE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EDITORIAL; GENETIC SCREENING; GENOTYPE; HUMAN; NANOANALYSIS; NANOMEDICINE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; TUMOR GROWTH; DRUG DESIGN; FORECASTING; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SYNTHESIS; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; FORECASTING; HUMANS; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NEOPLASMS;

EID: 84936950784     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.75     Document Type: Editorial

References (28)

1. Scudellari M. Drug development: try and try again. Nature S4-S6, 516 (2014).
2. Maciliwain C. Change the cancer conversation. Nature 520, 7 (2015).
3. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008).
4. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 501, 355-364 (2013).
5. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81 (2015).
6. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 339(6127), 1567-1570 (2013).
7. Kircher M, Witten DM, Jain P, O' Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46(3), 310-315 (2014).
8. Colditz GA, Sellera TA, Trapido E. Epidemiology-identifying the causes and preventability of cancer?. Nat. Rev. Cancer 675, 83 (2006).
9. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 287, 1969-1973 (2000).
10. Horton JK, Gleason JF Jr, Klepin HD, Isom S, Fried DB, Geiger AM. Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma. Cancer 117, 4033-4040 (2011).
11. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 341, 1192-1198 (2013).
12. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat. Rev. Clin. Oncol. 7, 653-664 (2012).
13. Hayden EC. Targeted treatment tests as potential cancer cure. Nature 479, 281 (2011).
14. Xue HY, Liu S, Wong HL. Nanotoxicity: carrying drugs. Nature 491, S58-S60 (2012).
15. Nigam SK. What do drug transporters really do?. Nat. Rev. Drug Discov. 14, 29-44 (2015).
16. Shiekh FA. Targeted nanotherapeutics in cancer. Int. J. Nanomedicine 9, 1627-28 (2014).
17. Service RF. Materials and biology. Nanotechnology takes aim at cancer. Science 310(5751), 1132-1134 (2005).
18. Hayden EC. Targeted treatment tested as potential cancer cure. Nature 479, 281 (2011).
19. Wright J. Deliver on a promise. Nature 509, S58-S59 (2014).
20. Shiekh FA. Highlights from recent advances in nanomedicine. Nanomedicine 9, 1287-1289 (2014).
21. Dong Y, Love KT, Dorkin JR, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111(11), 3955-3960 (2014).
22. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010).
23. Shiekh FA. Synthetic nanocarriers as a new paradigm. Nanomedicine 9, 2259-2262 (2014).
24. Mian SH, Patel N, Shah F, Arja SB, Shiekh FA. Research highlights from the International Journal of Nanomedicine 2014. Int. J. Nanomedicine 10, 2503-2505 (2015).
25. Tan YF, Mundargi RC, Chen MH, et al. Layer-by-layer nanoparticles for efficient siRNA delivery vehicle for SPARC silencing. Small 9, 295-312 (2014).
26. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 3, 242-244 (2008).
27. Gershon D. Toxicogenomics gains impetus. Nature 415, 4-5 (2002).
28. Riddihough G, Zahn LM. What is epigenetics?. Science 330(611), doi:10.1126/science.330.6004.611 (2010) (Epub ahead of print).